Rayence

228850 · KOSDAQ · Health Care · SMALL CAP

Back to an operating profit.

Rayence filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$24.6M (+34.9% year on year), operating profit of US$2.4M (from a loss a year earlier) and net income of US$3.92M (+2513.3% year on year).

Earnings(Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-05-12· RCEPT 20260512900401

US$24.6MRevenue
+34.9%Revenue vs a year earlier
US$2.4MOperating profit

Converted at 1 USD ≈ ₩1,492.99 (filing-date rate, 2026-05-12 close)

What happened

Rayence filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$24.6M (+34.9% year on year), operating profit of US$2.4M (from a loss a year earlier) and net income of US$3.92M (+2513.3% year on year).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$24.6M
Revenue vs a year earlier+34.9%
Operating profitUS$2.4M
Net incomeUS$3.92M
PeriodQ1 2026 (consolidated)
Filed2026-05-12, Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20260512900401 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-05-12 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.